Hematopoietic stem cell transplantation and implications for cell therapy reimbursement

Richard Maziarz, Dawn Driscoll

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

As costly stem cell treatments progress from experimental concepts toward licensed products and routine procedures, governmental and private payers grapple with shrinking budgets to cover more lives. We describe efforts underway in the US to create mechanisms for reimbursement of cell therapies and discuss other reimbursement-related issues for the stem cell community.

Original languageEnglish (US)
Pages (from-to)609-612
Number of pages4
JournalCell Stem Cell
Volume8
Issue number6
DOIs
StatePublished - Jun 3 2011

Fingerprint

Hematopoietic Stem Cell Transplantation
Cell- and Tissue-Based Therapy
Reimbursement Mechanisms
Stem Cells
Budgets
Therapeutics

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Medicine
  • Genetics

Cite this

Hematopoietic stem cell transplantation and implications for cell therapy reimbursement. / Maziarz, Richard; Driscoll, Dawn.

In: Cell Stem Cell, Vol. 8, No. 6, 03.06.2011, p. 609-612.

Research output: Contribution to journalArticle

@article{6ff6fc47307042a78b9b091ed4207761,
title = "Hematopoietic stem cell transplantation and implications for cell therapy reimbursement",
abstract = "As costly stem cell treatments progress from experimental concepts toward licensed products and routine procedures, governmental and private payers grapple with shrinking budgets to cover more lives. We describe efforts underway in the US to create mechanisms for reimbursement of cell therapies and discuss other reimbursement-related issues for the stem cell community.",
author = "Richard Maziarz and Dawn Driscoll",
year = "2011",
month = "6",
day = "3",
doi = "10.1016/j.stem.2011.05.013",
language = "English (US)",
volume = "8",
pages = "609--612",
journal = "Cell Stem Cell",
issn = "1934-5909",
publisher = "Cell Press",
number = "6",

}

TY - JOUR

T1 - Hematopoietic stem cell transplantation and implications for cell therapy reimbursement

AU - Maziarz, Richard

AU - Driscoll, Dawn

PY - 2011/6/3

Y1 - 2011/6/3

N2 - As costly stem cell treatments progress from experimental concepts toward licensed products and routine procedures, governmental and private payers grapple with shrinking budgets to cover more lives. We describe efforts underway in the US to create mechanisms for reimbursement of cell therapies and discuss other reimbursement-related issues for the stem cell community.

AB - As costly stem cell treatments progress from experimental concepts toward licensed products and routine procedures, governmental and private payers grapple with shrinking budgets to cover more lives. We describe efforts underway in the US to create mechanisms for reimbursement of cell therapies and discuss other reimbursement-related issues for the stem cell community.

UR - http://www.scopus.com/inward/record.url?scp=79957801289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957801289&partnerID=8YFLogxK

U2 - 10.1016/j.stem.2011.05.013

DO - 10.1016/j.stem.2011.05.013

M3 - Article

VL - 8

SP - 609

EP - 612

JO - Cell Stem Cell

JF - Cell Stem Cell

SN - 1934-5909

IS - 6

ER -